Breaking News

Financial Reports: Gilead

By Gil Roth | February 5, 2014

Stribild, Complera/Eviplera drive growth

Gilead 4Q13

4Q Revenues: $3.1 billion (+21%)

4Q Earnings: $791 million (+4%)

FY Revenues: $11.2 billion (+15%)

FY Earnings: $3.1 billion (+19%)

Comments: Product sales rose 21% in 4Q to $3.0 billion, driven by Stribild (+409% to $204 million), and Complera/Eviplera (+122% to $262 million). Atripla sales rose 2% to $934 million. In FY13, Atripla sales were up 2% to $3.6 billion, while Stribild posted $539 million (+837%) and Complera/Eviplera had $809 million in revenues (+137%). Gilead's cardiovascular franchise posted 24% gains in FY, with Letairis posting $520 million in sales (+27%) and Ranexa adding $449 million (+20%).
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision